Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) —innovative yet costly cholesterol-lowering agents—have been subject to substantial prior authorization (PA) requirements and low approval rates. We aimed to investigate trends in insurer approval and reasons for rejection for PCSK9i prescriptions as well as associations between patients’ demo graphic, clinical, pharmacy, payer, and PCSK9i-specific plan/coverage factors and approval.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research